NCT05065515

Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota

Establishment of Individualized Immunotherapy Strategy and Platform for Upper Gastrointestinal Cancer Based on Changes of Intestinal Microbiota

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To explore and analyze the relationship between intestinal flora changes and the efficacy of individualized immunotherapy in patients with upper gastrointestinal cancer, and to find new biomarkers to predict the efficacy of immunotherapy, bringing new breakthroughs in tumor diagnosis and treatment.

Detailed description

1. Compare the composition of intestinal flora of patients before and after immunotherapy and in patients with different therapeutic effects of immunotherapy. 2. Combine the results above with the patient's blood sample, which is carried out from the metabolic level. 3. Combine the pathological data of the patient to determine the staging and pathological types, and use blood samples to detect metabolites to find out different metabolites. 4. the metabolic data and the flora data are associated with the analysis to find the bacteria species with higher correlation with the differential metabolites to guide the subsequent animal experiments.

Conditions

• Gut Microbiota

Timeline

• Start date: 2021-10-01
• Primary completion: 2023-10-01
• Completion: 2023-12-01
• First posted: 2021-10-04
• Last updated: 2022-11-14

Locations

1 site across 1 country: China